Retrogenix joins trade delegation to Japan & South Korea


Members of the Retrogenix team have joined 21 other UK organisations as part of MedCity’s trade delegation to Japan and South Korea. The first leg of the trip includes visits to the Kobe Biomedical Innovation Cluster Symposium, a UK Life Sciences Symposium in Tokyo and an exhibition at the BioJapan conference in Yokohama.

The Japanese pharma market is ranked second in the world and is a key player in advanced therapies such as immunotherapies. Japan’s highly diverse market comprises traditionally domestically focused companies – often family formed – alongside highly globalised players. Retrogenix has seen a significant expansion in the number of receptor identification and off-target screening projects in the region over recent years and this visit helps strengthen existing relationships and gain more exposure within biotech companies in the area. 

Dr Mark Aspinall-O’Dea will also be presenting at BioJapan. His talk is entitled:

“Uncovering critical receptors and assessing target specificity of biotherapeutics”.

For further information on the trade mission, please visit the MedCity website.